Treatments

The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.

You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.

Become a Partner.

Country Product Indication Sponsor Date
Rifabutin Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection Adria Laboratories, Inc.;P.O. Box 16529;Columbus, Ohio, 43216 December 18, 1989
Rifabutin Disseminated Mycobacterium avium complex disease Pfizer Inc.;235 East 42nd Street;New York, New York, 10017 December 18, 1989
Carbovir Persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3 Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, North Carolina, 27709 December 13, 1989
4-aminosalicylic acid Ulcerative colitis Beeken, Warren M.D.;University Of Vermont, Given C-317;Burlington, Vermont, 05405 December 13, 1989
Multi-vitamin infusion (neonatal formula) For establishment and maintenance of total parenteral nutrition in very low birth weight infants Astra Pharmaceuticals, L.P.;725 Chesterbrook Blvd.;Wayne, Pennsylvania, 19087 December 12, 1989
Granulocyte macrophage-colony stimulating factor Neutropenia associated with bone marrow transplants Schering Corporation;2000 Galloping Hill Road;Kenilworth, New Jersey, 07033 December 12, 1989
Perfosfamide For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia Scios Nova, Inc.;2450 Bayshore Parkway;Mountain View, California, 94043 December 4, 1989
Corticorelin ovine triflutate For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome Ferring Laboratories, Inc.;400 Rella Boulevard, Suite 201;Suffern, New York, 10901 November 24, 1989
Bethanidine sulfate Prevention of recurrence of primary ventricular fibrillation Medco Research, Inc.;8455 Beverly Blvd., Suite 308;Los Angeles, California, 90048 November 24, 1989
CD4 human truncated 369 AA polypeptide Acquired immunodeficiency syndrome SmithKline Beecham;Route 23 & Woodmont Ave., P.O. Box 1510;King Of Prussia, Pennsylvania, 19406 November 21, 1989
Human immunodeficiency virus immune globulin AIDS NABI;5800 Park of Commerce Blvd., NW;Boca Raton, Florida, 33487 November 21, 1989
Human T-lymphotropic virus type III Gp160 antigens AIDS MicroGeneSys, Inc.;1000 Research Parkway;Meriden, Connecticut, 06450 November 20, 1989
3′-azido-2′,3’dideoxyuridine Acquired immunodeficiency syndrome Berlex Laboratories, Inc.;1401 Harbor Bay Parkway;Alameda, California, 94501 November 20, 1989
Recombinant soluble human CD4 Acquired immunodeficiency syndrome Biogen, Inc.;14 Cambridge Center;Cambridge, Massachusetts, 02142 November 20, 1989
Porfimer sodium Transitional cell carcinoma QLT Phototherapeutics, Inc.;Lederle Laboratories, 401 North Middletown Road;Pearl River, New York, 10965 November 15, 1989
Levocarnitine For the treatment of secondary carnitine deficiency in valproic acid toxicity Sigma-Tau Pharmaceuticals, Inc.;9841 Washingtonian Blvd, Suite500;Gaithersburg, MD, 20878 November 15, 1989
Levocarnitine For the prevention of secondary carnitine deficiency in valproic acid toxicity Sigma-Tau Pharmaceuticals, Inc.;9841 Washingtonian Blvd., Suite 500;Gaithersburg, MD, 20878 November 15, 1989
Levocarnitine 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. secondary carnitine deficiency in valproic acid toxicity Leadiant Biosciences, Inc.;9841 Washingtonian Blvd, Suite 500;Gaithersburg, Maryland, 20878 November 15, 1989
Interferon alfa-2a (recombinant) For use in combination with fluorouracil for the treatment of esophageal carcinoma Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07110 October 27, 1989
Fluorouracil For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07110 October 27, 1989
Pegaspargase Acute lymphoblastic leukemia Baxalta US, Inc.;650 Kendall Street;Cambridge, Massachusetts, 02142 October 20, 1989
Colfosceril palmitate, cetyl alcohol, tyloxapol Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, NC, 27709 October 20, 1989
Colfosceril palmitate, cetyl alcohol, tyloxapol Established hyaline membrane disease at all gestational ages Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, NC, 27709 October 20, 1989
Colfosceril palmitate, cetyl alcohol, tyloxapol Respiratory distress syndrome, infant Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, North Carolina, 27709 October 20, 1989
Enisoprost 1. For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine. G.D. Searle & Company;4901 Searle Parkway;Skokie, Illinois, 60077 October 20, 1989